Below is a list of the top companies exploring cell therapy treatments for diabetes. [Read more…]
We Interviewed Key Stem Cell Industry Leaders (Here’s What We Learned)
In groundbreaking news released January 2016, the Tisch MS Research Center of New York (MSRCNY) announced it is pursuing a Phase II clinical trial exploring spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (MSC-NPs) for the treatment of multiple sclerosis (MS).
Importantly, the Phase I trial was the first time in history that a treatment demonstrated reversal of established disability in MS patients. Therefore, we are excited to release an exclusive interview with Dr. Saud Sadiq, Chief Research Scientist for Tisch MSRCNY. [Read more…]
ViaCyte Acquires Rights to BetaLogics Assets for Stem Cell-Derived Approaches to Type 1 Diabetes
ViaCyte, Inc., announced news today that reverberated across the cell therapy community, stating it is acquiring an exclusive license to “all BetaLogics intellectual property in the field of metabolic disease, including diabetes, and the transfer of related assets to ViaCyte.” Importantly, this news positions ViaCyte as a leader in using stem cell therapy approaches for the treatment of Type 1 diabetes.
To learn more, read the full press release from ViaCyte below. [Read more…]